LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that in a clinical trial published in the August 2007 issue of the peer-reviewed journal Annals of Allergy, Asthma & Immunology (AAAI), ZYFLO CRTM (zileuton) extended-release tablets demonstrated significantly improved lung function in moderate persistent asthma patients compared to placebo. Separately, the results from a clinical trial of the immediate –release formulation of zileuton, ZYFLO® (zileuton tablets), demonstrating safety in patients with chronic asthma were published in the Drug Safety edition of the Official Journal of the International Society of Pharmacovigilance.
